Targeting Carnitine Acetyltransferase Activity to Senescence‑Dependent Metabolic Switching Preserves Beneficial SASP While Preventing Chronic Accumulation

Hypothesis

Transient activation of carnitine acetyltransferase (CAT) in senescent muscle cells shifts their metabolism from a persistent fatty‑acid‑oxidation (FAO) state to a balanced acetyl‑CoA buffer, thereby maintaining a reparative SASP and preventing the lipid‑overload that drives chronic inflammation.

Mechanistic rationale

• Senescent myoblasts accumulate long‑chain acyl‑carnitines, indicating excess FAO and insufficient CAT‑mediated acetyl‑group buffering 4.
• Elevated FAO fuels DDR‑mitochondria signaling that raises acetyl‑CoA, cristae remodeling and p16 expression, locking cells in a senescence‑promoting loop 5.
• CAT normally converts acetyl‑CoA + carnitine ↔ acetyl‑carnitine + CoA, providing a sink for excess acetyl groups and linking FAO to the TCA cycle.
• We propose that a decline in CAT activity or Vmax during the acute‑to‑chronic transition creates a metabolic bottleneck: acyl‑carnitines rise, FAO stays high, and the SASP shifts from transient, pro‑regenerative factors to a maladaptive, inflammatory cocktail.

Novel insight

Unlike senolytics that remove the cell, modulating CAT activity preserves the senescent cell’s chaperone‑like signaling while correcting the metabolic inflection point. Early after injury, a boost in CAT activity would limit acyl‑carnitine buildup, sustain a SASP rich in IGF‑1, FGF‑2 and IL‑6 that promotes dedifferentiation of neighboring myoblasts (as seen in salamander limb regeneration) 1. In aged tissue, sustained CAT activation would prevent the metabolic stall that converts these chaperones into drivers of atrophy and fibrosis.

Testable predictions

1. Enzyme kinetics – Senescent human myoblasts will show a lower CAT Vmax and/or higher Km for acetyl‑CoA compared with proliferating myoblasts.
2. Pharmacologic/genetic activation – Treatment with a CAT activator (e.g., small‑molecule allosteric modulator) or CAT overexpression will decrease intracellular long‑chain acyl‑carnitines, increase acetyl‑carnitine flux, and reduce FAO‑derived ROS without lowering p16 levels.
3. SASP re‑profiling – CAT activation will shift the secretory profile toward transient repair factors (IGF‑1, HGF, VEGF) and away from chronic inflammatory cytokines (IL‑1β, TNF‑α, MCP‑1).
4. Functional outcome in vivo – Transplantation of senescent muscle cells into young injured mice, combined with CAT activator administration, will enhance regeneration (greater central‑nucleated fiber count, less fibrosis) compared with transplantation alone; the same treatment in aged mice will attenuate atrophy and improve grip strength.
5. Falsifiability – If CAT modulation fails to alter acyl‑carnitine concentrations, SASP composition, or tissue repair outcomes, the hypothesis is refuted.

Experimental approach

• In vitro: Induce senescence in C2C12 myoblasts (10 Gy IR). Use CRISPRa to up‑regulate CAT or shRNA to knock it down; treat with L‑carnitine (1 mM) and a putative CAT activator (to be identified via screening). Measure acyl‑carnitine LC‑MS, Seahorse FAO, acetyl‑carnitine production, SASP by ELISA, and neighbor myoblast proliferation (BrdU incorporation).
• In vivo: Generate senescent donor cells (irradiated C2C12) labeled with GFP. Transplant into tibialis anterior of young (2 mo) and old (24 mo) mice. Administer CAT activator via osmotic pump (dose based on in‑vitro EC50). Assess muscle cross‑sectional area, central nucleation, fibrosis (Masson’s Trichrome), systemic cytokines, and grip strength at 7 and 14 days post‑transplant.
• Controls: Vehicle, senolytic (dasatinib+quercetin) to compare clearance versus metabolic intervention.

Implications

If validated, targeting CAT offers a senomorphic strategy that retains the beneficial chaperone functions of senescent cells while preventing their pathogenic conversion, providing a therapeutic window distinct from broad senolytic ablation.